Group 1 - The stock price of Beilu Zhikong (301195.SZ) closed at 37.55 yuan, down 4.65%, currently below the issue price [1] - Beilu Zhikong was listed on the Shenzhen Stock Exchange's ChiNext on August 1, 2022, with an issuance of 21,920,290 shares, accounting for 25% of the post-issue total share capital, at an issue price of 71.17 yuan per share [1] - The total funds raised by Beilu Zhikong amounted to 156,006.70 million yuan, with a net amount of 143,080.79 million yuan after deducting issuance costs of 12,925.92 million yuan [1] Group 2 - The net amount raised was 82,244.07 million yuan more than the original plan of 60,836.72 million yuan, which was intended for the construction of intelligent mining equipment production lines, the establishment of an intelligent mining R&D center, and to supplement working capital [1] - The total issuance costs (excluding tax) were 12,925.92 million yuan, with Huatai United Securities receiving underwriting and sponsorship fees of 10,920.47 million yuan [1] - The 2022 annual profit distribution plan was approved at the shareholders' meeting on May 8, 2023, with a cash dividend of 9 yuan per 10 shares, totaling 78,913,044 yuan, and a capital reserve conversion of 5 shares for every 10 shares [2]

Group 1 - The core point of the news is that Huasheng Lithium Electric (688353.SH) is currently experiencing a decline in stock price, closing at 33.42 yuan with a drop of 5.33%, indicating it is in a state of loss since its IPO [1] - Huasheng Lithium Electric was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on July 13, 2022, with an issuance of 28 million shares at a price of 98.35 yuan per share [1] - The highest price recorded for Huasheng Lithium Electric since its listing was 129.20 yuan on July 15, 2022, just two days after its IPO [1] Group 2 - The company raised a total of 2.754 billion yuan through its initial public offering, with a net amount of 2.567 billion yuan after deducting issuance costs of 187 million yuan [1] - The net fundraising amount exceeded the original plan by 1.867 billion yuan, indicating strong investor interest [1] - The funds raised are intended for projects including the annual production of 6,000 tons of vinyl carbonate and 3,000 tons of fluorinated ethylene carbonate, as well as the construction of a research and development center [1] Group 3 - On May 10, 2023, Huasheng Lithium Electric announced a profit distribution plan, which included a cash dividend of 1 yuan per share and a capital reserve increase of 0.45 shares for all shareholders [2] - The record date for the rights distribution was set for May 9, 2023, with the ex-dividend date on May 10, 2023 [2]

2023年6月8日，本立科技发布2022年年度权益分派实施公告。公司2022年年度权益分派方案为：以公司 现有总股本70,680,000股为基数，向全体股东每10股派1.500000元人民币现金，同时，以资本公积金向 全体股东每10股转增5.000000股。本次权益分派股权登记日为2023年6月15日，除权除息日为2023年6月 16日。 本立科技于2021年9月14日在深交所创业板上市，发行股票数量为1768万股，占发行后总股本的比例为 25.01%，发行价格为42.50元/股，保荐机构为长城证券（002939）股份有限公司，保荐代表人为刘逢 敏、郑益甫。上市首日，本立科技盘中创下股价高点112.99元。 中国经济网北京8月14日讯今日，本立科技（301065）(301065.SZ)收报24.25元，跌幅6.69%，目前该股 股价低于发行价。 本立科技公开发行新股的发行费用合计6814.48万元，其中长城证券股份有限公司获得保荐、承销费用 (不含增值税)4724.91万元。 本立科技募集资金总额为7.51亿元，扣除发行费用后，募集资金净额为6.83亿元。本立科技最终募集资 金净额比原计划多2.07亿元。本立 ...

诚达药业首次公开发行股票的发行费用总额为13,576.31万元，其中，保荐承销费用11,792.90万元。 2023年7月3日，诚达药业发布2022年度权益分派实施公告。公司2022年年度权益分派方案为：以公司现 有总股本96,696,140股为基数，向全体股东每10股派3.000000元人民币现金，同时，以资本公积金向全 体股东每10股转增6.000000股。本次权益分派股权登记日为2023年7月6日，除权除息日为2023年7月7 日。 诚达药业首次公开发行股票募集资金总额为175,721.06万元，扣除发行费用后募集资金净额162,144.75万 元。诚达药业实际募资净额比原拟募集资金多110,816.71万元。诚达药业于2022年1月14日披露的招股说 明书显示，该公司原拟募集资金51,328.04万元，分别用于"医药中间体项目、原料药项目及研发中心扩 建项目"和"补充流动资金"。 中国经济网北京8月14日讯诚达药业（301201）(301201.SZ)今日股价下跌，截至收盘报27.34元，跌幅 5.50%，该股目前处于破发状态。 诚达药业于2022年1月20日在深交所创业板上市，公开发行新股2,417 ...

中国经济网北京8月6日讯中红医疗（300981）(300981.SZ)今日收报13.51元，跌幅2.60%。 中红医疗于2021年4月27日在深交所创业板上市，公开发行股票4167万股，发行价格为48.59元/股，保 荐机构(主承销商)是海通证券(现名"国泰海通证券股份有限公司")，保荐代表人是张子慧、雷浩。 上市首日，中红医疗盘中最高价报159.80元，创该股上市以来最高价，此后该股股价震荡下跌。该股目 前处于破发状态。 中红医疗首次公开发行股票的发行费用总额为1.28亿元，其中海通证券获得保荐及承销费用1.07亿元。 中红医疗于2023年5月19日发布的2022年年度权益分派实施公告显示，2022年度利润分配及资本公积金 转增股本方案为：以公司现有总股本300,006,000股(截止公告发布日无回购股份)为基数，向全体股东每 10股派发现金7.00元(含税)，送红股0股(含税)，以资本公积金向全体股东每10股转增3股，即合计派发 现金红利210,004,200.00元(含税)，转增后公司总股本增加90,001,800股，剩余未分配利润结转以后年度 分配。 中红医疗于2022年5月24日发布的2021年年度 ...

Core Viewpoint - The company, Jiemite (300868.SZ), announced a share reduction plan involving several shareholders, which may impact the stock's market performance but will not change the company's control or significantly affect its ongoing operations [1][4]. Shareholder Reduction Plans - Huang Xin, holding 7,674,336 shares (6% of total shares), plans to reduce his holdings by 1,240,000 shares (0.978%) within three months after the announcement [1]. - Yang Shaoxu, with 415,500 shares (0.325%), intends to reduce his holdings by 415,500 shares (0.328%) in the same timeframe [1]. - Liu Hui, holding 6,900 shares (0.005%), plans to reduce by 6,900 shares (0.005%) [2]. - Li Yun, with 1,039 shares (0.001%), aims to reduce by 1,039 shares (0.001%) [2]. - Bian Erli, holding 18,397 shares (0.014%), plans to reduce by 18,397 shares (0.015%) [2]. - Chen Guangping, with 215,000 shares (0.168%), intends to reduce by 215,000 shares (0.170%) [3]. - Liu Shuwei, holding 34,297 shares (0.027%), plans to reduce by 8,500 shares (0.007%) [3]. - In total, the seven shareholders hold 8,365,469 shares and plan to reduce 1,905,336 shares, accounting for 1.504% of total shares [4][5]. Financial Performance - Jiemite's financial performance has shown fluctuations, with net profits for the years 2021 to 2024 being -116 million, -91.62 million, 707,000, and 7.07 million respectively [7]. - The company's revenue for 2023 was approximately 676.48 million, a decrease of 5.93% from 2022 [8]. - The net profit attributable to shareholders for 2023 was -91.62 million, while the net profit excluding non-recurring items was 133.35 million, indicating a significant recovery from previous losses [8]. - In the first quarter of 2025, the company reported a revenue of 150 million, a decline of 29.10% year-on-year, with a net profit of -3.66 million [9].

Core Viewpoint - The company Jiemite (300868.SZ) announced a share reduction plan involving several shareholders, which will not affect the company's control or ongoing operations significantly [1][4][5]. Shareholder Reduction Plans - Shareholder Huang Xin plans to reduce holdings by 1,240,000 shares, representing 0.978% of the total shares after excluding repurchased shares [1][4]. - Shareholder Yang Shaoxu intends to reduce holdings by 415,500 shares, accounting for 0.328% of the total shares after excluding repurchased shares [1][2]. - Other shareholders, including Liu Hui, Li Yun, Bian Erli, Chen Guangping, and Liu Shuwei, also have plans to reduce their holdings, with total planned reductions amounting to 1,905,336 shares, or 1.504% of the total shares [4][5]. Financial Performance - Jiemite's financial performance has shown fluctuations, with net profits for the years 2021 to 2024 being 28.22 million, -116 million, -91.62 million, and 707,000 respectively [7]. - The company's revenue for 2023 was approximately 676.48 million, a decrease of 5.93% from 2022 [8]. - In 2024, the company expects a revenue increase to approximately 761.64 million, reflecting a 12.59% growth compared to 2023 [9]. Company Background - Jiemite was listed on the Shenzhen Stock Exchange on August 24, 2020, with an initial public offering price of 41.26 yuan per share, raising a net amount of approximately 118.97 million yuan [6]. - The company has faced challenges, with its stock currently trading below its initial offering price, indicating a state of underperformance [6].

Group 1 - Zhongyi Technology (301150) closed at 25.57 yuan, with a decline of 5.16% [1] - The company was listed on the Shenzhen Stock Exchange's ChiNext board on April 21, 2022, with an initial public offering (IPO) of 16.837 million shares at a price of 163.56 yuan per share [1] - The total funds raised from the IPO amounted to 2.754 billion yuan, with a net amount of 2.603 billion yuan, exceeding the original plan by 1.887 billion yuan [1] Group 2 - In June 2022, the company announced a cash dividend of 20 yuan per 10 shares, totaling 134.69 million yuan, and a stock bonus of 5 shares for every 10 shares held, increasing the total share capital to 101.02 million shares [2] - In June 2023, the company declared a cash dividend of 13 yuan per 10 shares, totaling 131.33 million yuan, and a stock bonus of 3 shares for every 10 shares held, raising the total share capital to 131.33 million shares [2] Group 3 - In May 2024, the company announced a dividend plan of 1 yuan per 10 shares, with a stock bonus of 4 shares for every 10 shares held [3] - In May 2025, the company revealed a dividend plan with no cash dividend, but a stock bonus of 3 shares for every 10 shares held, increasing the total share capital to 233.23 million shares [3]

Group 1 - The core point of the article highlights the current stock performance of Huasheng Lithium Battery, which has seen a decline of 5.82% to a closing price of 31.90 yuan [1] - Huasheng Lithium Battery was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on July 13, 2022, with an initial offering of 28 million shares at a price of 98.35 yuan per share [1] - The stock reached its highest price of 129.20 yuan on July 15, 2022, just three trading days after its listing, but is currently in a state of decline [1] - The company raised a total of 2.754 billion yuan from its initial public offering, with a net amount of 2.567 billion yuan after deducting issuance costs of 187 million yuan [1] - The net fundraising amount exceeded the original plan by 1.867 billion yuan, with the funds intended for projects including the production of 6,000 tons of vinyl carbonate and 3,000 tons of fluorinated vinyl carbonate, as well as the establishment of a research and development center [1] Group 2 - On May 10, 2023, Huasheng Lithium Battery announced a profit distribution plan, which includes a cash dividend of 1 yuan per share (tax included) and a capital reserve increase of 0.45 shares for each share held [2] - The record date for the equity distribution was set for May 9, 2023, with the ex-dividend date on May 10, 2023 [2]

长华化学上市发行募集资金总额为90,253.75万元，扣除发行费用后，募集资金净额为82,505.94万元。该 公司最终募集资金净额比原计划多52,446.44万元。长华化学于2023年7月28日披露的招股说明书显示， 其拟募集资金30,059.50万元，分别用于信息系统建设、研发中心项目、营销网络建设、补充流动资金和 偿还银行贷款。 长华化学本次发行费用总额为7,747.81万元，其中，保荐及承销费用5,184.17万元。 长华化学于2023年8月3日在深交所创业板上市，公开发行股票3,505万股，占发行后公司股份总数的比 例为25.00%，发行价格为25.75元/股，保荐人(主承销商)为东吴证券股份有限公司，保荐代表人为陈 勇、尹鹏。 中国经济网北京7月29日讯长华化学（301518）(301518.SZ)今日收报22.08元，跌幅3.07%，总市值30.95 亿元。目前该股处于破发状态。 ...